Rhabdovirus-based vaccine platforms against henipaviruses

Journal of Virology

Volumn 89, Issue 1, 2015, Pages 144-154

  Kurup, Drishya ^a   Wirblich, Christoph ^a   Feldmann, Heinz ^b   Marzi, Andrea ^b   Schnell, Matthias J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIVE VACCINE; VIRUS VACCINE; ATTACHMENT PROTEIN G; DRUG CARRIER; INACTIVATED VACCINE; NEUTRALIZING ANTIBODY; RECOMBINANT VACCINE; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CODON; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EXPRESSION VECTOR; HENDRA VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NIPAH VIRUS INFECTION; NONHUMAN; PROTEIN DENATURATION; RESTRICTION SITE; ULTRAVIOLET SPECTROPHOTOMETRY; VIRION; VIRUS NEUTRALIZATION; VIRUS PARTICLE; VIRUS RECOMBINANT; VIRUS STRAIN; VIRUS VIRULENCE; ADVERSE DRUG REACTION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; GENE VECTOR; GENETICS; HENDRA VIRUS; HENIPAVIRUS INFECTIONS; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; PROCEDURES; RABIES VIRUS; VACCINATION; VESICULOVIRUS;

HENDRA VIRUS; HENIPAVIRUS; MUS; NIPAH VIRUS; PARAMYXOVIRIDAE; RABIES VIRUS; RHABDOVIRIDAE; VESICULAR STOMATITIS VIRUS;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DRUG CARRIERS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENETIC VECTORS; HENDRA VIRUS; HENIPAVIRUS INFECTIONS; INJECTIONS, INTRAMUSCULAR; MICE; MICE, INBRED BALB C; RABIES VIRUS; VACCINATION; VACCINES, ATTENUATED; VACCINES, INACTIVATED; VACCINES, SYNTHETIC; VESICULOVIRUS; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EID: 84919458610     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02308-14     Document Type: Article

References (63)

1. Eaton BT, Broder CC, Middleton D, Wang LF. 2006. Hendra and Nipah viruses: different and dangerous. Nat Rev Microbiol 4:23-35. http://dx.doi.org/10.1038/nrmicro1323.
2. Lee B, Rota PA. 2012. Henipavirus-ecology, molecular virology, and pathogenesis. Curr Top Microbiol Immunol 359:41-58. http://dx.doi.org/10.1007/82_2012_211.
3. Hsu VP. 2007. Emerging viruses in human populations-Nipah and Hendra viruses, vol 16. Elsevier, Amsterdam, The Netherlands.
4. Marsh GA, Wang LF. 2012. Hendra and Nipah viruses: why are they so deadly?. Curr Opin Virol 2:242-247. http://dx.doi.org/10.1016/j.coviro.2012.03.006.
5. Field H, Young P, Yob JM, Mills J, Hall L, Mackenzie J. 2001. The natural history of Hendra and Nipah viruses. Microbes Infect 3:307-314. http://dx.doi.org/10.1016/S1286-4579(01)01384-3.
6. Young PL, Halpin K, Selleck PW, Field H, Gravel JL, Kelly MA, Mackenzie JS. 1996. Serologic evidence for the presence in Pteropus bats of a paramyxovirus related to equine morbillivirus. Emerg Infect Dis 2:239-240. http://dx.doi.org/10.3201/eid0203.960315.
7. Aljofan M. 2013. Hendra and Nipah infection: emerging paramyxoviruses. Virus Res 177:119-126. http://dx.doi.org/10.1016/j.virusres.2013.08.002.
8. Mohd Nor MN, Gan CH, Ong BL. 2000. Nipah virus infection of pigs in peninsular Malaysia. Rev. Sci Tech 19:160-165.
9. Steffen DL, Xu K, Nikolov DB, Broder CC. 2012. Henipavirus mediated membrane fusion, virus entry and targeted therapeutics. Viruses 4:280-308. http://dx.doi.org/10.3390/v4020280.
10. Xu K, Broder CC, Nikolov DB. 2012. Ephrin-B2 and ephrin-B3 as functional henipavirus receptors. Semin Cell Dev Biol 23:116-123. http://dx.doi.org/10.1016/j.semcdb.2011.12.005.
11. Mellitzer G, Xu Q, Wilkinson DG. 1999. Eph receptors and ephrins restrict cell intermingling and communication. Nature 400:77-81. http://dx.doi.org/10.1038/21907.
12. Su Z, Xu P, Ni F. 2004. Single phosphorylation of Tyr304 in the cytoplasmic tail of ephrin B2 confers high-affinity and bifunctional binding to both the SH2 domain of Grb4 and the PDZ domain of the PDZ-RGS3 protein. Eur J Biochem 271:1725-1736. http://dx.doi.org/10.1111/j.1432-1033.2004.04078.x.
13. Gale NW, Baluk P, Pan L, Kwan M, Holash J, DeChiara TM, McDonald DM, Yancopoulos GD. 2001. Ephrin-B2 selectively marks arterial vessels and neovascularization sites in the adult, with expression in both endothelial and smooth-muscle cells. Dev Biol 230:151-160. http://dx.doi.org/10.1006/dbio.2000.0112.
14. Negrete OA, Chu D, Aguilar HC, Lee B. 2007. Single amino acid changes in the Nipah and Hendra virus attachment glycoproteins distinguish ephrinB2 from ephrinB3 usage. J Virol 81:10804-10814. http://dx.doi.org/10.1128/JVI.00999-07.
15. Bossart KN, Crameri G, Dimitrov AS, Mungall BA, Feng YR, Patch JR, Choudhary A, Wang LF, Eaton BT, Broder CC. 2005. Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus. J Virol 79:6690-6702. http://dx.doi.org/10.1128/JVI.79.11.6690-6702.2005.
16. Bossart KN, Zhu Z, Middleton D, Klippel J, Crameri G, Bingham J, McEachern JA, Green D, Hancock TJ, Chan YP, Hickey AC, Dimitrov DS, Wang LF, Broder CC. 2009. A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute Nipah virus infection. PLoS Pathog 5:e1000642. http://dx.doi.org/10.1371/journal.ppat.1000642.
17. Prabakaran P, Zhu Z, Xiao X, Biragyn A, Dimitrov AS, Broder CC, Dimitrov DS. 2009. Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses. Expert Opin Biol Ther 9:355-368. http://dx.doi.org/10.1517/14712590902763755.
18. Bossart KN, Geisbert TW, Feldmann H, Zhu Z, Feldmann F, Geisbert JB, Yan L, Feng YR, Brining D, Scott D, Wang Y, Dimitrov AS, Callison J, Chan YP, Hickey AC, Dimitrov DS, Broder CC, Rockx B. 2011. A neutralizing human monoclonal antibody protects African green monkeys from Hendra virus challenge. Sci Transl Med 3:105ra103. http://dx.doi.org/10.1126/scitranslmed.3002901.
19. Geisbert TW, Mire CE, Geisbert JB, Chan YP, Agans KN, Feldmann F, Fenton KA, Zhu Z, Dimitrov DS, Scott DP, Bossart KN, Feldmann H, Broder CC. 2014. Therapeutic treatment of Nipah virus infection in nonhuman primates with a neutralizing human monoclonal antibody. Sci Transl Med 6:242ra282. http://dx.doi.org/10.1126/scitranslmed.3008929.
20. DeBuysscher BL, Scott D, Marzi A, Prescott J, Feldmann H. 2014. Single-dose live-attenuated Nipah virus vaccines confer complete protection by eliciting antibodies directed against surface glycoproteins. Vaccine 32:2637-2644. http://dx.doi.org/10.1016/j.vaccine.2014.02.087.
21. Mire CE, Versteeg KM, Cross RW, Agans KN, Fenton KA, Whitt MA, Geisbert TW. 2013. Single injection recombinant vesicular stomatitis virus vaccines protect ferrets against lethal Nipah virus disease. Virol J 10: 353. http://dx.doi.org/10.1186/1743-422X-10-353.
22. Lo MK, Bird BH, Chattopadhyay A, Drew CP, Martin BE, Coleman JD, Rose JK, Nichol ST, Spiropoulou CF. 2014. Single-dose replicationdefective VSV-based Nipah virus vaccines provide protection from lethal challenge in Syrian hamsters. Antiviral Res 101:26-29. http://dx.doi.org/10.1016/j.antiviral.2013.10.012.
23. Ploquin A, Szecsi J, Mathieu C, Guillaume V, Barateau V, Ong KC, Wong KT, Cosset FL, Horvat B, Salvetti A. 2013. Protection against henipavirus infection by use of recombinant adeno-associated virusvector vaccines. J Infect Dis 207:469-478. http://dx.doi.org/10.1093/infdis/jis699.
24. Mire CE, Geisbert JB, Agans KN, Feng YR, Fenton KA, Bossart KN, Yan L, Chan YP, Broder CC, Geisbert TW. 2014. A recombinant Hendra virusGglycoprotein subunit vaccine protects nonhuman primates against Hendra virus challenge. J Virol 88:4624-4631. http://dx.doi.org/10.1128/JVI.00005-14.
25. Bossart KN, Rockx B, Feldmann F, Brining D, Scott D, LaCasse R, Geisbert JB, Feng YR, Chan YP, Hickey AC, Broder CC, Feldmann H, Geisbert TW. 2012. A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge. Sci Transl Med 4:146ra107. http://dx.doi.org/10.1126/scitranslmed.3004241.
26. Mendez D, Buttner P, Speare R. 2013. Response of Australian veterinarians to the announcement of a Hendra virus vaccine becoming available. Aust Vet J 91:328-331. http://dx.doi.org/10.1111/avj.12092.
27. Vos A, Neubert A, Aylan O, Schuster P, Pommerening E, Muller T, Chivatsi DC. 1999. An update on safety studies of SAD B19 rabies virus vaccine in target and non-target species. Epidemiol Infect 123:165-175. http://dx.doi.org/10.1017/S0950268899002666.
28. McGettigan JP, Pomerantz RJ, Siler CA, McKenna PM, Foley HD, Dietzschold B, Schnell MJ. 2003. Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 Gag have greatly reduced pathogenicity but are highly immunogenic. J Virol 77:237-244. http://dx.doi.org/10.1128/JVI.77.1.237-244.2003.
29. Gomme EA, Wirblich C, Addya S, Rall GF, Schnell MJ. 2012. Immune clearance of attenuated rabies virus results in neuronal survival with altered gene expression. PLoS Pathog 8:e1002971. http://dx.doi.org/10.1371/journal.ppat.1002971.
30. Schnell MJ, Foley HD, Siler CA, McGettigan JP, Dietzschold B, Pomerantz RJ. 2000. Recombinant rabies virus as potential live-viral vaccines for HIV-1. Proc Natl Acad Sci USA 97:3544-3549. http://dx.doi.org/10.1073/pnas.97.7.3544.
31. Dietzschold B, Wunner WH, Wiktor TJ, Lopes AD, Lafon M, Smith CL, Koprowski H. 1983. Characterization of an antigenic determinant of the glycoprotein that correlates with pathogenicity of rabies virus. Proc Natl Acad Sci USA 80:70-74. http://dx.doi.org/10.1073/pnas.80.1.70.
32. Lawson ND, Stillman EA, Whitt MA, Rose JK. 1995. Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci USA 92:4477-4481. http://dx.doi.org/10.1073/pnas.92.10.4477.
33. Roberts A, Buonocore L, Price R, Forman J, Rose JK. 1999. Attenuated vesicular stomatitis viruses as vaccine vectors. J Virol 73:3723-3732.
34. Blaney JE, Marzi A, Willet M, Papaneri AB, Wirblich C, Feldmann F, Holbrook M, Jahrling P, Feldmann H, Schnell MJ. 2013. Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine. PLoS Pathog 9:e1003389. http://dx.doi.org/10.1371/journal.ppat.1003389.
35. Schnell MJ, Buonocore L, Whitt MA, Rose JK. 1996. The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus. J Virol 70:2318-2323.
36. Harty RN, Brown ME, Hayes FP, Wright NT, Schnell MJ. 2001. Vaccinia virus-free recovery of vesicular stomatitis virus. J Mol Microbiol Biotechnol 3:513-517.
37. Papaneri AB, Wirblich C, Marissen WE, Schnell MJ. 2013. Alanine scanning of the rabies virus glycoprotein antigenic site III using recombinant rabies virus: implication for post-exposure treatment. Vaccine 31: 5897-5902. http://dx.doi.org/10.1016/j.vaccine.2013.09.038.
38. Lefrancois L, Lyles DS. 1982. The interaction of antibody with the major surface glycoprotein of vesicular stomatitis virus. I. Analysis of neutralizing epitopes with monoclonal antibodies. Virology 121:157-167.
39. National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.
40. Blaney JE, Wirblich C, Papaneri AB, Johnson RF, Myers CJ, Juelich TL, Holbrook MR, Freiberg AN, Bernbaum JG, Jahrling PB, Paragas J, Schnell MJ. 2011. Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. J Virol 85:10605-10616. http://dx.doi.org/10.1128/JVI.00558-11.
41. Gomme EA, Wanjalla CN, Wirblich C, Schnell MJ. 2011. Rabies virus as a research tool and viral vaccine vector. Adv Virus Res 79:139-164. http://dx.doi.org/10.1016/B978-0-12-387040-7.00009-3.
42. Papaneri AB, Wirblich C, Cann JA, Cooper K, Jahrling PB, Schnell MJ, Blaney JE. 2012. A replication-deficient rabies virus vaccine expressing Ebola virus glycoprotein is highly attenuated for neurovirulence. Virology 434:18-26. http://dx.doi.org/10.1016/j.virol.2012.07.020.
43. Kretzschmar E, Buonocore L, Schnell MJ, Rose JK. 1997. Highefficiency incorporation of functional influenza virus glycoproteins into recombinant vesicular stomatitis viruses. J Virol 71:5982-5989.
44. Marzi A, Feldmann H, Geisbert TW, Falzarano D. 2011. Vesicular stomatitis virus-based vaccines for prophylaxis and treatment of filovirus infections. J Bioterror Biodef 2011(Suppl 1):2157-2526-S1-004. http://dx.doi.org/10.4172/2157-2526.S1-004.
45. Ramsburg E, Rose NF, Marx PA, Mefford M, Nixon DF, Moretto WJ, Montefiori D, Earl P, Moss B, Rose JK. 2004. Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol. J Virol 78:3930-3940. http://dx.doi.org/10.1128/JVI.78.8.3930-3940.2004.
46. Faber M, Lamirande EW, Roberts A, Rice AB, Koprowski H, Dietzschold B, Schnell MJ. 2005. A single immunization with a rhabdovirusbased vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARSCoV-neutralizing antibodies. J Gen Virol 86:1435-1440. http://dx.doi.org/10.1099/vir.0.80844-0.
47. McKenna PM, Koser ML, Carlson KR, Montefiori DC, Letvin NL, Papaneri AB, Pomerantz RJ, Dietzschold B, Silvera P, McGettigan JP, Schnell MJ. 2007. Highly attenuated rabies virus-based vaccine vectors expressing simian-human immunodeficiency virus89.6P Env and simian immunodeficiency virus mac239 Gag are safe in rhesus macaques and protect from an AIDS-like disease. J Infect Dis 195:980-988. http://dx.doi.org/10.1086/512243.
48. Schell JB, Rose NF, Bahl K, Diller K, Buonocore L, Hunter M, Marx PA, Gambhira R, Tang H, Montefiori DC, Johnson WE, Rose JK. 2011. Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen. J Virol 85: 5764-5772. http://dx.doi.org/10.1128/JVI.00342-11.
49. Schnell MJ, Buonocore L, Kretzschmar E, Johnson E, Rose JK. 1996. Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles. Proc Natl Acad Sci USA 93:11359-11365. http://dx.doi.org/10.1073/pnas.93.21.11359.
50. Middleton D, Pallister J, Klein R, Feng YR, Haining J, Arkinstall R, Frazer L, Huang JA, Edwards N, Wareing M, Elhay M, Hashmi Z, Bingham J, Yamada M, Johnson D, White J, Foord A, Heine HG, Marsh GA, Broder CC, Wang LF. 2014. Hendra virus vaccine, a one health approach to protecting horse, human, and environmental health. Emerg Infect Dis 20:372-379. http://dx.doi.org/10.3201/eid2003.131159.
51. Gomme EA, Faul EJ, Flomenberg P, McGettigan JP, Schnell MJ. 2010. Characterization of a single-cycle rabies virus-based vaccine vector. J Virol 84:2820-2831. http://dx.doi.org/10.1128/JVI.01870-09.
52. Schwartz JA, Buonocore L, Suguitan A, Jr, Hunter M, Marx PA, Subbarao K, Rose JK. 2011. Vesicular stomatitis virus-based H5N1 avian influenza vaccines induce potent cross-clade neutralizing antibodies in rhesus macaques. J Virol 85:4602-4605. http://dx.doi.org/10.1128/JVI.02491-10.
53. + cells of recombinant vesicular stomatitis viruses encoding human immunodeficiency virus envelope proteins. J Virol 71:5060-5068.
54. + target cells by recombinant rabies virus pseudotypes carrying the HIV-1 envelope spike protein. Proc Natl Acad Sci USA 93:11366-11370. http://dx.doi.org/10.1073/pnas.93.21.11366.
55. Khetawat D, Broder CC. 2010. A functional henipavirus envelope glycoprotein pseudotyped lentivirus assay system. Virol J 7:312. http://dx.doi.org/10.1186/1743-422X-7-312.
56. Tamin A, Harcourt BH, Lo MK, Roth JA, Wolf MC, Lee B, Weingartl H, Audonnet JC, Bellini WJ, Rota PA. 2009. Development of a neutralization assay for Nipah virus using pseudotype particles. J Virol Methods 160:1-6. http://dx.doi.org/10.1016/j.jviromet.2009.02.025.
57. Siler CA, McGettigan JP, Dietzschold B, Herrine SK, Dubuisson J, Pomerantz RJ, Schnell MJ. 2002. Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines. Virology 292:24-34. http://dx.doi.org/10.1006/viro.2001.1212.
58. Johnson JE, Rodgers W, Rose JK. 1998. A plasma membrane localization signal in the HIV-1 envelope cytoplasmic domain prevents localization at sites of vesicular stomatitis virus budding and incorporation into VSV virions. Virology 251:244-252. http://dx.doi.org/10.1006/viro.1998.9429.
59. Rose JK, Bergmann JE. 1983. Altered cytoplasmic domains affect intracellular transport of the vesicular stomatitis virus glycoprotein. Cell 34: 513-524. http://dx.doi.org/10.1016/0092-8674(83)90384-7.
60. Foley HD, McGettigan JP, Siler CA, Dietzschold B, Schnell MJ. 2000. A recombinant rabies virus expressing vesicular stomatitis virus glycoprotein fails to protect against rabies virus infection. Proc Natl Acad Sci USA 97:14680-14685. http://dx.doi.org/10.1073/pnas.011510698.
61. Witting SR, Vallanda P, Gamble AL. 2013. Characterization of a third generation lentiviral vector pseudotyped with Nipah virus envelope proteins for endothelial cell transduction. Gene Ther 20:997-1005. http://dx.doi.org/10.1038/gt.2013.23.
62. Faber M, Faber ML, Li J, Preuss MA, Schnell MJ, Dietzschold B. 2007. Dominance of a nonpathogenic glycoprotein gene over a pathogenic glycoprotein gene in rabies virus. J Virol 81:7041-7047. http://dx.doi.org/10.1128/JVI.00357-07.
63. Schulte S, Sukhova GK, Libby P. 2008. Genetically programmed biases in Th1 and Th2 immune responses modulate atherogenesis. Am J Pathol 172:1500-1508. http://dx.doi.org/10.2353/ajpath.2008.070776.